Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA

Anticancer Research

Volumn 17, Issue 4 B, 1997, Pages 2993-2994

  Wolff, J M ^a,c   Boeckmann, W ^a   Effert, P J ^a   Habib, F K ^b   Jakse, G ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Benign prostate hyperplasia; Cancer of the prostate; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLOOD LEVEL; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; EARLY DIAGNOSIS; ENZYME IMMUNOASSAY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 0030775568     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (3)

1. Catalona WJ, Richie JP, Ahmann FR et al: Comparison of digital rectal examination and serum prostate specific antigen (PSA) in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 51: 1283-1290, 1994.
2. Stenman UH, Leinonen J, Alfthan H, Ranniko S, Tuhkanen K, Alfthan O: A complex between prostate-specific antigen and alpha 1 antichymotrypsin is the major form of prostate-specific antigen in the serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 5: 222-226, 1991.
3. Lilja H, Christensson A, Dahlen U et al: Prostate-specific antigen in serum occurs predominantly in complex with alpha-1-antichymotrypsin. Clin Chem 37: 1618-1625, 1991.